secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266974
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised
--------------------------------------------------------------------------------

- Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.
- MRD revenue $56.8M (+52% YoY); MRD achieved profitability and cash flow positivity with Adj. EBITDA $7.0M.
- clonoSEQ test volume 27,111 (+38% YoY); NCCN guidelines updated for CLL MRD-guided treatment duration.
- Net income $9.5M vs $32.1M loss in Q3 2024; Adj. EBITDA $28.0M vs $14.3M loss.
- FY2025 MRD revenue guidance raised to $202-207M; total operating spend and cash burn guidance reduced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/0001193125-25-266974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312525266974/adpt-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer